查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1750848

再生医学市场规模、份额、趋势分析报告：按产品、治疗类别、地区、细分市场预测，2025-2030 年

Regenerative Medicine Market Size, Share & Trends Analysis Report By Product (Therapeutics, Tools, Banks), By Therapeutic Category (Dermatology, Musculoskeletal, Immunology & Inflammation), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 245 Pages | 商品交期: 2-10个工作天内

价格

再生医学市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球再生医学市场规模预计在2025年至2030年期间以16.83%的复合年增长率增长，到2030年将达到900.1亿美元。

强大的产品线是再生医学市场的主要驱动力之一，因为公司正在大力投资研发，以最新技术升级其产品并满足客户未满足的需求。

此外，随着疾病治疗需求的不断增长，各公司正致力于加速针对基因组层面疾病病因的基因疗法的研发。根据美国药物研究与製造商协会（PhRMA）发布的数据，美国在研项目（I-III期临床试验）中的细胞和基因治疗药物数量从2018年的289种增加到2019年的362种，一年内增加了25%。该领域的持续进步可能会进一步刺激再生医学的需求。

干细胞、组织工程、奈米技术和其他技术的进步使再生医学成为一个高度跨学科的领域。干细胞是未分化的细胞，具有修復和再生其他细胞（例如软骨、肌腱、韧带、肌肉和骨骼）的能力。 2021年7月，BlueRock Therapeutics公司获得FDA核准，其多功能细胞衍生的多巴胺能神经元疗法DA01用于治疗进行性帕金森氏症。此次核准预计将扩大该公司的产品阵容。

一些关键参与者正在采取新产品开发和策略联盟等策略性倡议，促进再生医学市场的成长。例如，2021年11月，Astellas来製药与Pantherna Therapeutics GmbH签署协议，共同研究基于mRNA的再生医学。根据该协议，Astellas来製药强大的药物研发能力和Pantherna先进的mRNA平台将用于推进新专案的研究和开发。此外，2021年5月，拜耳股份公司与Senti Bio签署了一项合作研究协议，旨在开发结合基因迴路的再生医学细胞疗法。

再生医学市场报告重点

  • 由于老龄化社会的进展和与老龄化的疾病的增加，治疗药物部分占据再生医学市场的最大份额。
  • 预计针对干细胞和组织再生疗法的临床试验的增加以及对再生疗法的需求的不断增长将对市场成长产生积极影响。
  • 由于研发方面的巨大投入和干细胞库的增加，基于干细胞和前驱细胞的治疗方法预计将经历显着增长。
  • 由于北美地区有大量从事干细胞治疗方法研究和开发的研究机构和大学，预计到 2024 年北美将占据市场主导地位。
  • 由于医疗保健行业迅速采用基于细胞的方法，预计亚太地区将在未来几年见证最快的成长。
  • 从治疗领域来看，肿瘤治疗将在2024年占据市场主导地位，因为全球癌症患者数量的成长推动了对更优解决方案的需求。强劲且不断成长的产品线正在推动市场成长。

目录

第一章调查方法与范围

第二章执行摘要

第三章市场变数、趋势和范围

  • 市场展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场趋势与展望
    • 市场动态
    • 市场限制因素分析
  • 商业环境分析
    • PESTEL分析
    • 波特五力分析
    • COVID-19影响分析

第四章 产品业务分析

  • 细分仪表板
  • 全球再生医学市场：产品趋势分析
  • 治疗
    • 初代细胞治疗
    • 基于干细胞和前驱细胞的治疗方法
    • 细胞免疫疗法
    • 基因治疗
  • 工具
  • 银行
  • 服务

5. 治疗类别业务分析

  • 细分仪表板
  • 全球再生医学市场：治疗类别变化分析
  • 皮肤科
  • 肌肉骨骼
  • 免疫学和炎症
  • 肿瘤学
  • 心血管系统
  • 眼科
  • 其他的

第六章区域业务分析

  • 2024 年及 2030 年全球再生医学市场占有率
  • 北美洲
    • 2018-2030年北美再生医学市场
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2018-2030年欧洲再生医学市场
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2018-2030年亚太再生医学市场
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 2018-2030年拉丁美洲再生医学市场
    • 巴西
    • 阿根廷
  • 中东和非洲
    • MEA 再生医学市场，2018-2030
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 公司分类
  • 战略地图
  • 2024年企业市场分析
  • 公司简介/列表
    • AstraZeneca plc.
    • F. Hoffmann-La Roche Ltd.
    • Integra Lifesciences Corp.
    • Astellas Pharma, Inc.
    • Cook Biotech, Inc.
    • Bayer AG
    • Pfizer, Inc.
    • Merck KGaA
    • Abbott
    • Vericel Corp.
    • Novartis AG
    • GlaxoSmithKline
Product Code: GVR-1-68038-952-4

Regenerative Medicine Market Growth & Trends:

The global regenerative medicine market size is expected to reach USD 90.01 billion by 2030, expanding at a CAGR of 16.83% from 2025 to 2030, according to a new report by Grand View Research, Inc. The presence of a strong pipeline is one of the major drivers in the regenerative medicine market. Companies invest heavily in R&D to upgrade their products with the latest technology and fulfil the unmet needs of their customers.

Furthermore, with the increasing demand for disease treatment therapies, companies have focused their efforts to accelerate R&D for gene therapies that target the cause of disease at a genomic level. The cell and gene therapies in the U.S. pipeline programs (Phase I-III trials) grew from 289 in 2018 to 362 by 2019 according to the data published by PhRMA,. This represents an increase of 25% in a single year. Continuous advancements in this field would further boost the demand for regenerative medicines.

Technological advancements such as stem cells, tissue engineering, and nanotechnology has made regenerative medicines a highly interdisciplinary in field. Stem cells are undifferentiated cells, which have the capability to repair and/or regenerate into other cells such as cartilage, tendons, ligaments, muscle, and bones. In July 2021, BlueRock Therapeutics received FDA approval for its pluripotent stem cell-derived dopaminergic neuron therapy, DA01, for advanced Parkinson's disease treatment. This approval was expected to expand the company's offerings.

Several key players are taking strategic initiatives such as new product development, strategic alliances, and others have contributed to the regenerative medicine market growth. For instance, in November 2021, Astellas Pharma, Inc. entered into an agreement with Pantherna Therapeutics GmbH to study mRNA-based regenerative medicine. Under this initiative, Astellas' high drug discovery capabilities and Pantherna's state-of-the-art mRNA platform will be used to promote research on developing a new program. In addition, in May 2021, Bayer AG entered into a collaboration with Senti Bio for gene circuit-engineered cell therapies development for regenerative medicine.

Regenerative Medicine Market Report Highlights:

  • The therapeutics segment held the largest share in the regenerative medicine market, owing to the growing aging population coupled with an increasing rate of age-related disorders.
  • The rise in a number of clinical trials for stem cell and tissue-based regenerative therapies along with an increase in demand for regenerative therapies is expected to positively influence the growth of the market.
  • Stem cell and progenitor cell-based therapies are projected to witness significant growth owing to huge investments in the R&D space and a growing number of stem cell banks
  • North America dominated the market in 2024 owing to the presence of a significant number of research organizations and universities which are working on R&D of stem cell-based therapies.
  • Asia Pacific is anticipated to witness the fastest growth in the coming years owing to the rapid adoption of cell-based methods in the healthcare industry.
  • By therapeutic category, the oncology segment dominated the segment in 2024 owing to the increasing cases of cancer globally which is rising the demand for better solutions. The growing number of robust pipelines is driving the market growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Therapeutic Category
  • 1.3. Research Methodology
  • 1.4. Information Procurement
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
    • 3.2.1. Market Dynamics
      • 3.2.1.1. Presence of a strong pipeline and a large number of clinical trials
      • 3.2.1.2. High economic impact of regenerative medicine
      • 3.2.1.3. Emerging applications of gene therapy in regenerative medicine
      • 3.2.1.4. Increasing government & private funding to support the development of regenerative medicine
      • 3.2.1.5. Technological advancements in regenerative medicine (stem cell, tissue engineering, and nanotechnology)
      • 3.2.1.6. Increase in strategic partnerships to accelerate the development & commercialization of regenerative medicines
      • 3.2.1.7. Rising prevalence of chronic diseases & genetic disorders, degenerative diseases, and bone & joint diseases leading to a rise in demand for regenerative treatments
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Regulatory issues pertaining to stem cells, tissue engineering, and regenerative medicines
  • 3.3. Business Environment Analysis
    • 3.3.1. PESTEL Analysis
    • 3.3.2. Porter's Five Forces Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Regenerative Medicine Market: Product Movement Analysis
  • 4.3. Therapeutics
    • 4.3.1. Therapeutics Market, 2018 - 2030 (USD Million)
    • 4.3.2. Primary Cell-Based Therapeutics
      • 4.3.2.1. Primary Cell-Based Therapeutics Market, 2018 - 2030 (USD Million)
      • 4.3.2.2. Dermatology
        • 4.3.2.2.1. Dermatology Market, 2018 - 2030 (USD Million)
      • 4.3.2.3. Musculoskeletal
        • 4.3.2.3.1. Musculoskeletal Market, 2018 - 2030 (USD Million)
      • 4.3.2.4. Surgical
        • 4.3.2.4.1. Surgical Market, 2018 - 2030 (USD Million)
      • 4.3.2.5. Dental
        • 4.3.2.5.1. Dental Market, 2018 - 2030 (USD Million)
      • 4.3.2.6. Others
        • 4.3.2.6.1. Others Market, 2018 - 2030 (USD Million)
    • 4.3.3. Stem Cell & Progenitor Cell-based therapeutics
      • 4.3.3.1. Stem Cell & Progenitor Cell-based therapeutics Market, 2018 - 2030 (USD Million)
      • 4.3.3.2. Autologous
        • 4.3.3.2.1. Autologous Market, 2018 - 2030 (USD Million)
      • 4.3.3.3. Allogenic
        • 4.3.3.3.1. Allogenic Market, 2018 - 2030 (USD Million)
      • 4.3.3.4. Others
        • 4.3.3.4.1. Others Market, 2018 - 2030 (USD Million)
    • 4.3.4. Cell-based Immunotherapies
      • 4.3.4.1. Cell-based Immunotherapies Market, 2018 - 2030 (USD Million)
    • 4.3.5. Gene Therapies
      • 4.3.5.1. Gene Therapies Market, 2018 - 2030 (USD Million)
  • 4.4. Tools
    • 4.4.1. Tools Market, 2018 - 2030 (USD Million)
  • 4.5. Banks
    • 4.5.1. Banks Market, 2018 - 2030 (USD Million)
  • 4.6. Services
    • 4.6.1. Services Market, 2018 - 2030 (USD Million)

Chapter 5. Therapeutic Category Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Regenerative Medicine Market: Therapeutic Category Movement Analysis
  • 5.3. Dermatology
    • 5.3.1. Dermatology Market, 2018 - 2030 (USD Million)
  • 5.4. Musculoskeletal
    • 5.4.1. Musculoskeletal Market, 2018 - 2030 (USD Million)
  • 5.5. Immunology & Inflammation
    • 5.5.1. Immunology & Inflammation Market, 2018 - 2030 (USD Million)
  • 5.6. Oncology
    • 5.6.1. Oncology Market, 2018 - 2030 (USD Million)
  • 5.7. Cardiovascular
    • 5.7.1. Cardiovascular Market, 2018 - 2030 (USD Million)
  • 5.8. Ophthalmology
    • 5.8.1. Ophthalmology Market, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Regional Business Analysis

  • 6.1. Global Regenerative Medicine Market Share By Region, 2024 & 2030
  • 6.2. North America
    • 6.2.1. North America Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. Key Country Dynamics
      • 6.2.2.2. Competitive Scenario
      • 6.2.2.3. Regulatory Framework
      • 6.2.2.4. U.S. Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Competitive Scenario
      • 6.2.3.3. Regulatory Framework
      • 6.2.3.4. Canada Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Key Country Dynamics
      • 6.2.4.2. Competitive Scenario
      • 6.2.4.3. Regulatory Framework
      • 6.2.4.4. Mexico Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.2. Germany
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Competitive Scenario
      • 6.3.2.3. Regulatory Framework
      • 6.3.2.4. Germany Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.3. UK
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Competitive Scenario
      • 6.3.3.3. Regulatory Framework
      • 6.3.3.4. UK Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Competitive Scenario
      • 6.3.4.3. Regulatory Framework
      • 6.3.4.4. France Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Competitive Scenario
      • 6.3.5.3. Regulatory Framework
      • 6.3.5.4. Italy Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Competitive Scenario
      • 6.3.6.3. Regulatory Framework
      • 6.3.6.4. Spain Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Competitive Scenario
      • 6.3.7.3. Regulatory Framework
      • 6.3.7.4. Denmark Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Competitive Scenario
      • 6.3.8.3. Regulatory Framework
      • 6.3.8.4. Sweden Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Competitive Scenario
      • 6.3.9.3. Regulatory Framework
      • 6.3.9.4. Norway Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Competitive Scenario
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Japan Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.3. China
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Competitive Scenario
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. China Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Competitive Scenario
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. India Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Competitive Scenario
      • 6.4.5.3. Regulatory Framework
      • 6.4.5.4. South Korea Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Competitive Scenario
      • 6.4.6.3. Regulatory Framework
      • 6.4.6.4. Australia Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Competitive Scenario
      • 6.4.7.3. Regulatory Framework
      • 6.4.7.4. Thailand Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Brazil Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Argentina Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 6.6. MEA
    • 6.6.1. MEA Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. South Africa Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Saudi Arabia Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. UAE Regenerative Medicine Market, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Competitive Scenario
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Kuwait Regenerative Medicine Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Market Position Analysis, 2024
  • 7.4. Company Profiles/Listing
    • 7.4.1. AstraZeneca plc.
      • 7.4.1.1. Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. F. Hoffmann-La Roche Ltd.
      • 7.4.2.1. Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Integra Lifesciences Corp.
      • 7.4.3.1. Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Astellas Pharma, Inc.
      • 7.4.4.1. Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Cook Biotech, Inc.
      • 7.4.5.1. Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. Bayer AG
      • 7.4.6.1. Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Pfizer, Inc.
      • 7.4.7.1. Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Merck KGaA
      • 7.4.8.1. Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Abbott
      • 7.4.9.1. Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Vericel Corp.
      • 7.4.10.1. Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives
    • 7.4.11. Novartis AG
      • 7.4.11.1. Overview
      • 7.4.11.2. Financial Performance
      • 7.4.11.3. Product Benchmarking
      • 7.4.11.4. Strategic Initiatives
    • 7.4.12. GlaxoSmithKline
      • 7.4.12.1. Overview
      • 7.4.12.2. Financial Performance
      • 7.4.12.3. Product Benchmarking
      • 7.4.12.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviations
  • Table 3 Global Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 4 Global Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 5 North America Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
  • Table 6 North America Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 7 North America Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 8 U.S Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 9 U.S Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 10 Canada Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 11 Canada Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 12 Mexico Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 13 Mexico Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 14 Europe Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
  • Table 15 Europe Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 16 Europe Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 17 Germany Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 18 Germany Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 19 U.K Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 20 U.K Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 21 France Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 22 France Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 23 Italy Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 24 Italy Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 25 Spain Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 26 Spain Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 27 Denmark Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 28 Denmark Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 29 Norway Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 30 Norway Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 31 Sweden Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 32 Sweden Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 36 China Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 37 China Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 38 Japan Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 39 Japan Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 40 India Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 41 India Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 42 Australia Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 43 Australia Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 44 South Korea Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 45 South Korea Regenerative Medicine Market, by services, 2018 - 2030 (USD Million)
  • Table 46 Thailand Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 47 Thailand Regenerative Medicine Market, by services, 2018 - 2030 (USD Million)
  • Table 48 Latin America Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
  • Table 49 Latin America Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 50 Latin America Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 51 Brazil Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 52 Brazil Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 53 Argentina Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 54 Argentina Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 55 Middle East & Africa Regenerative Medicine Market, by Country, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 58 South Africa Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 59 South Africa Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 62 UAE Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 63 UAE Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 64 Kuwait Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Regenerative Medicine Market, By Therapeutic Category, 2018 - 2030 (USD Million)
  • Table 66 Participant's Overview
  • Table 67 Financial Performance
  • Table 68 Key Companies Undergoing Expansions
  • Table 69 Key Companies Undergoing Acquisitions
  • Table 70 Key Companies Undergoing Collaborations
  • Table 71 Key Companies Launching New Products/Services
  • Table 72 Key Companies Undergoing Partnerships
  • Table 73 Key Companies Undertaking Other Strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary Others pattern
  • Fig. 4 Market Others approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market summary, 2024 (USD Million)
  • Fig. 9 Market segmentation & scope
  • Fig. 10 Market driver impact
  • Fig. 11 Market restraint impact
  • Fig. 12 Porter's analysis
  • Fig. 13 SWOT analysis
  • Fig. 14 Global regenerative medicine therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 15 Global primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 16 Global dermatology primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 17 Global musculoskeletal primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 18 Global surgical primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 19 Global dental primary cell-bases therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 20 Global other primary cell-based therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 21 Global autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 22 Global autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 23 Global allogeneic stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 24 Global other stem cell & progenitor cell-based therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 25 Global cell-based immunotherapies market, 2018 - 2030 (USD Million)
  • Fig. 26 Global gene therapies market, 2018 - 2030 (USD Million)
  • Fig. 27 Global regenerative medicines tools, 2018 - 2030 (USD Million)
  • Fig. 28 Global banks market for regenerative medicine, 2018 - 2030 (USD Million)
  • Fig. 29 Global regenerative medicine services market, 2018 - 2030 (USD Million)
  • Fig. 30 Regenerative medicine market: Therapeutic category outlook and key takeaways
  • Fig. 31 Regenerative medicine market: Therapeutic category movement analysis (USD Million)
  • Fig. 32 Global dermatological therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 33 Global musculoskeletal therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 34 Global immunology & inflammation therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 35 Global oncology therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 36 Global cardiovascular therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 37 Global ophthalmology therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 38 Global other therapeutics category market, 2018 - 2030 (USD Million)
  • Fig. 39 Global Regenerative Medicine Market: Regional outlook and key takeaways
  • Fig. 40 North America Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 41 U.S key country dynamics
  • Fig. 42 U.S Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 43 Canada key country dynamics
  • Fig. 44 Canada Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 45 Mexico key country dynamics
  • Fig. 46 Mexico Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Europe Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Germany key country dynamics
  • Fig. 49 Germany Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 France key country dynamics
  • Fig. 51 France Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 U.K key country dynamics
  • Fig. 53 U.K Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Italy key country dynamics
  • Fig. 55 Italy Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 56 Spain key country dynamics
  • Fig. 57 Spain Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 58 Denmark key country dynamics
  • Fig. 59 Denmark Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 60 Sweden key country dynamics
  • Fig. 61 Sweden Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Norway key country dynamics
  • Fig. 63 Norway Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Asia-Pacific Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 65 China key country dynamics
  • Fig. 66 China Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 India key country dynamics
  • Fig. 68 India Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 69 South Korea key country dynamics
  • Fig. 70 South Korea Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 71 Japan key country dynamics
  • Fig. 72 Japan Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 73 Australia key country dynamics
  • Fig. 74 Australia Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Thailand key country dynamics
  • Fig. 76 Thailand Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 77 Latin America Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 Brazil key country dynamics
  • Fig. 79 Brazil Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 Argentina key country dynamics
  • Fig. 81 Argentina Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 MEA Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 83 South Africa key country dynamics
  • Fig. 84 South Africa Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 85 Saudi Arabia key country dynamics
  • Fig. 86 Saudi Arabia Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 87 UAE key country dynamics
  • Fig. 88 UAE Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 89 Kuwait key country dynamics
  • Fig. 90 Kuwait Regenerative Medicine Market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 91 Market participant categorization
  • Fig. 92 Strategy framework